Paul Mead is a Principal Scientist and Director of the Translational Immunopathology laboratory in the Department of Pathology at St Jude Children’s Research Hospital. The Translational Immunopathology laboratory is responsible for developing new flow cytometry assays for the Clinical Immunopathology laboratory, where Dr Mead also serves as Technical Director, and to develop and conduct flow assays to support research aims for St Jude-led clinical trials. The Translational Immunopathology laboratory also supports St Jude’s Global Pathology and Laboratory Medicine’s mission to provide training and assay development for pediatric hematopathologists and clinical flow labs in resource-limited settings across the globe. Dr Mead received his undergraduate and graduate degrees in Biochemistry from Massey University, New Zealand and post-doctoral training at Harvard Medical School in the Department of Hematology/Oncology, Children’s Hospital, Boston. As an independent, NIH-funded investigator in the Department of Pathology, St Jude Children’s Research Hospital, Dr Mead’s research interests focused on the development of the hematopoietic system during early embryonic development. For more than a decade, Dr Mead has been the Director of the Translational Immunopathology laboratory where his research interests have focused on immunophenotyping and minimal residual disease detection of pediatric hematopoietic malignancies. Most recently, these efforts have been directed towards developing high-parameter spectral flow cytometry panels for diagnosis and treatment follow-up of pediatric leukemias in the clinical laboratory setting.